SecurityGUAA / Guaranty Bancorp, Inc.
IndustryState Commercial Banks
Common Shares Outstanding29,305,602 shares (as of 2017-12-31)
Total Insiders24
Total Directors10
Total Officers12

Stock Insider Trading (from SEC Form 4)

Guaranty Bancorp, Inc. insider trades are listed in the following table, followed by a table containing the full transaction history. Insiders are officers, directors, or significant investors in a company. In general, it is generally illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4.

GUAA / Guaranty Bancorp, Inc. insiders include BATCHELDER DAVID H, Miltimore Joseph E., and Noesen Michael J, Treece Christopher G, Joyce Stephen D, Pizzichini Anthony L., Erickson Christopher E, Finger Keith R., BRENNAN SUZANNE R, RELATIONAL INVESTORS LLC, Dickelman Keith, CORDES EDWARD B, Hobbs Michael B, O'Brien Patrick Dan, Apt Justin WYCOFF W KIRK, WHITWORTH RALPH V, YATES ALBERT C, Goss Cathy P, TAYLOR PAUL W, MCCONAHEY STEPHEN G, DiPetro Michael J, EGGEMEYER JOHN M III, KLAPPER GAIL H, .

Insider Roster

Insider Dir Off 10% Shares Owned
X 17,878
X 25,716
X 1,397,066
X 1,588,093
Finger Keith R. Director
X 75,241
X 3,196
X 42,995
Joyce Stephen D Director
X 64,010
O'Brien Patrick Dan EVP, Regional Pres., SBA Mgr.
X 27,052
Apt Justin Managing Principal
X 10,718
Erickson Christopher E EVP, Real Estate Banking
X 19,606
DiPetro Michael J EVP, Retail Banking Manager
X 3,419
Dickelman Keith EVP, Business Banking
X 25,512
TAYLOR PAUL W President & CEO, Director
X X 98,603
Pizzichini Anthony L. EVP, Regional President
X 25,581
Miltimore Joseph E. EVP, Middle Market
X 16,092
Noesen Michael J EVP, Credit Administration
X 44,219
Treece Christopher G EVP, CFO & Secretary
X 40,002
Hobbs Michael B President, Guaranty Bank
X 42,950
Goss Cathy P EVP & CCO
X 69,384
X 32,291

Transaction History

Click the link icon to see the full transaction history. Transactions reported as part of a 10b-5 automatic trading plan will have an X in the column marked 10b-5.

Form Insider Code 10b-5 Direct Share
Post Value
2018-05-07 4 Joyce Stephen D A D 1,022 64,010
2018-05-07 4 CORDES EDWARD B A D 1,476 42,995
2018-05-07 4 BRENNAN SUZANNE R A D 1,022 3,196
2018-05-07 4 Finger Keith R. A D 1 75,241
2018-05-07 4 EGGEMEYER JOHN M III By Castle Creek Advisors IV LP A I 1,022 1,588,093
2018-05-07 4 WYCOFF W KIRK By Patriot Financial Manager, LP A I 1,022 1,397,066
2018-05-07 4 KLAPPER GAIL H A D 1,022 25,716
2018-05-07 4 MCCONAHEY STEPHEN G A D 1,022 17,878
2018-05-01 4 Apt Justin G D -36 10,718
2018-04-30 4 O'Brien Patrick Dan S D 28.65 -696 27,052 775,040
2018-04-27 4 O'Brien Patrick Dan S D 29 -820 27,748 804,692
2018-04-24 4 Erickson Christopher E S D 29.238 -680 19,606 573,240
2018-04-23 4 Dickelman Keith S D 29.40 -2,000 25,512 750,053
2018-04-23 4 DiPetro Michael J S D 29.40 -689 3,419 100,519
2018-04-13 4 TAYLOR PAUL W A D 1,640 98,603
2018-03-28 4 Erickson Christopher E F D 28.35 -320 20,286
2018-03-28 4 Noesen Michael J F D 28.35 -480 44,219
2018-03-28 4 DiPetro Michael J F D 28.35 -311 4,108
2018-03-28 4 Miltimore Joseph E. F D 28.35 -320 16,092
2018-03-28 4 O'Brien Patrick Dan F D 28.35 -480 28,568
2018-03-28 4 Pizzichini Anthony L. F D 28.35 -630 25,581
2018-03-16 4 O'Brien Patrick Dan S D 29.40 -696 29,048 854,011
2018-03-15 4 O'Brien Patrick Dan S D 29.30 -820 29,744 871,499
2018-03-13 4 Miltimore Joseph E. S D 29.26 -2,200 16,412 480,215
2018-03-08 4 Erickson Christopher E S D 28.9931 -2,589 20,606 597,432
2018-03-08 4 Noesen Michael J S D 28.8967 -7,500 24,699 713,720
2018-03-02 4 Joyce Stephen D P D 27.4565 96 62,988 1,729,441
2018-02-22 4 DiPetro Michael J S D 28.2959 -2,162 4,419 125,040
2018-02-12 4 O'Brien Patrick Dan A D 1,439 30,564
2018-02-12 4 O'Brien Patrick Dan M D 2,086 29,125
2018-02-12 4 O'Brien Patrick Dan F D 27.80 -688 27,039
2018-02-07 4 O'Brien Patrick Dan F D 27.75 -173 27,727
2018-02-05 4 O'Brien Patrick Dan F D 27.25 -519 27,900
2018-02-12 4 Apt Justin A D 1,799 10,754
2018-02-12 4 Apt Justin F D 27.80 -733 8,955
2018-02-12 4 Apt Justin M D 1,738 9,688
2018-02-07 4 Apt Justin F D 27.75 -318 7,950
2018-02-05 4 Apt Justin F D 27.25 -791 8,268
2018-02-12 4 Miltimore Joseph E. A D 1,349 18,612
2018-02-12 4 Miltimore Joseph E. M D 1,912 17,263
2018-02-12 4 Miltimore Joseph E. F D 27.80 -652 15,351
2018-02-07 4 Miltimore Joseph E. F D 27.75 -173 16,003
2018-02-05 4 Miltimore Joseph E. F D 27.25 -594 16,176
2018-02-12 4 Dickelman Keith A D 899 27,512
2018-02-12 4 Erickson Christopher E A D 1,529 23,195
2018-02-12 4 Erickson Christopher E M D 2,086 21,666
2018-02-12 4 Erickson Christopher E F D 27.80 -715 19,580
2018-02-07 4 Erickson Christopher E F D 27.75 -173 20,295
2018-02-05 4 Erickson Christopher E F D 27.25 -463 20,468
2018-02-12 4 DiPetro Michael J A D 1,079 6,581
Open market or private purchase of non-derivative or derivative security
Open market or private sale of non-derivative or derivative security
Grant, award, or other acquisition of securities from the company (such as an option)
Conversion of derivative
Sale or transfer of securities back to the company
Payment of exercise price or tax liability using portion of securities received from the company
Gift of securities by or to the insider
Equity swaps and similar hedging transactions
Exercise or conversion of derivative security received from the company (such as an option)
A transaction voluntarily reported on Form 4
Other (accompanied by a footnote describing the transaction)

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

Related News Stories

Deals of the day-Mergers and acquisitions

2018-05-23 reuters
May 23 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 1000 GMT on Wednesday: (67-0)

Independent Bank to buy Guaranty Bancorp for about $1 bln

2018-05-22 reuters
(Reuters) - Independent Bank Group Inc said on Tuesday it would buy Guaranty Bancorp for about $1 billion to expand its operations in the state of Colorado. (14-0)

Surprise, Surprise: No Strategy Works All The Time

2017-12-12 seekingalpha
Very few, if any, would have predicted our Momentum model's 55%+ return so far in 2017. (13-0)